Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
231 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04142437 | Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body(ON-TRK) | recruiting | — | 150 | BayerINDUSTRY | 26 | Jul 7, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY |
| 23 |
| Jul 7, 2026 |
| clinicaltrials |
| NCT07408193 | The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain. | recruiting | Early Phase 1 | 24 | National and Kapodistrian University of AthensOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | recruiting | Phase 3 | 665 | CelgeneINDUSTRY | 22 | Jul 1, 2026 | clinicaltrials |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | recruiting | Phase 1 / Phase 2 | 616 | Revolution Medicines, Inc.INDUSTRY | 13 | Jun 30, 2026 | clinicaltrials |
| NCT06716814 | Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa(LIBERTY) | recruiting | Phase 3 | 104 | Swedish Orphan BiovitrumINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT02834884 | SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access(SPECTA) | recruiting | — | 4,975 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 20 | Jun 24, 2026 | clinicaltrials |
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | recruiting | Phase 2 | 70 | Innate PharmaINDUSTRY | 5 | Jun 17, 2026 | clinicaltrials |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | recruiting | Phase 1 / Phase 2 | 258 | SanofiINDUSTRY | 10 | Jun 16, 2026 | clinicaltrials |
| NCT07200427 | MELIORA Virtual Coach Intervention for Breast Cancer Prevention(MELIORA) | recruiting | N/A | 2,080 | Harokopio UniversityOTHER | 4 | Jun 15, 2026 | clinicaltrials |
| NCT07642362 | Digital Support for Multiple Myeloma Quality of Life(DigiMyQoL) | recruiting | N/A | 108 | CareAcrossINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642375 | Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients(SARC-Digital) | recruiting | N/A | 108 | CareAcrossINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05890677 | The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema(LYMPH) | recruiting | N/A | 280 | University Hospital, Basel, SwitzerlandOTHER | 15 | Jun 4, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06404983 | Opioid-free Anaesthesia in Breast Cancer Surgery | recruiting | N/A | 200 | University of IoanninaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT05099471 | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia(VIWA-1) | recruiting | Phase 2 | 80 | Christian BuskeOTHER | 2 | May 5, 2026 | clinicaltrials |
| NCT06716294 | Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By Positron Emission Computed Tomography (PET-CT) Confirmation(ABLASPINE) | recruiting | — | 16 | National and Kapodistrian University of AthensOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06079970 | Confocal Laser Endomicroscopy VERification(CLEVER) | recruiting | N/A | 208 | Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)OTHER | 5 | Apr 7, 2026 | clinicaltrials |
| NCT07510061 | Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals(ICARUS) | recruiting | N/A | 80 | University of ThessalyOTHER | 2 | Apr 3, 2026 | clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT05879757 | Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency | recruiting | — | 75 | TakedaINDUSTRY | 11 | Feb 18, 2026 | clinicaltrials |
| NCT06830759 | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma(EpcoReal) | recruiting | — | 700 | AbbVieINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT07389408 | A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing(PRELUDE) | recruiting | — | 2,000 | National and Kapodistrian University of AthensOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | recruiting | Phase 2 | 127 | Karyopharm Therapeutics IncINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT07328087 | COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer(COLONYVAQ™-CRC) | recruiting | Early Phase 1 | 12 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07292246 | A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)(ATHENA I) | recruiting | N/A | 15 | Vasileios KallesOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT07077616 | Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.(TAMAVAQTM) | recruiting | Early Phase 1 | 29 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
| NCT07210164 | Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study(Pre_ERAS) | recruiting | N/A | 100 | Aristotle University Of ThessalonikiOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | AB ScienceINDUSTRY | 4 | Oct 2, 2025 | clinicaltrials |
| NCT06779890 | Effect of Volatile- Based Versus Total Intravenous Anesthesia on Brain Homeostasis and Neurocognitive Outcome(TIVolBrain) | recruiting | Phase 4 | 84 | Georgia TsaousiOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07190066 | MELIORA Data Collection Campaigns(DCC) | recruiting | N/A | 300 | Harokopio UniversityOTHER | 4 | Sep 30, 2025 | clinicaltrials |
| NCT04064359 | Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | recruiting | Phase 1 | 200 | Oxford BioTherapeutics LtdINDUSTRY | 5 | Sep 16, 2025 | clinicaltrials |
| NCT04949646 | Intraoperative Neuromonitoring of Pelvic Autonomous Nerve Plexus During Total Mesorectal Excision | recruiting | N/A | 44 | Larissa University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials